RAC2 and neoplasm: From the perspective of immune invasion, we systematically associated RAC2 with immune characteristics in the tumor microenvironment (TME) [27], including immunomodulators, immune checkpoint inhibitors, and tumor-infiltrating immune cells (TIICs).